Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NRG Energy Inc (NRG) vs Novartis AG (NVS) Price & Performance

NRG Energy IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

NRG Energy Inc vs Novartis AG — how do they compare? NRG Energy Inc trades at $116.91 (market cap $25.15B), while Novartis AG trades at $138.16 (market cap $262.64B). The key difference: Novartis AG is far larger — about 10.4× NRG Energy Inc's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.

NRGNVS
Market Cap
$25.15B$262.64B
Sector
UtilitiesHealth
52-Week High
$184.03$168.62
52-Week Low
$109.51$121.80
Enterprise Value
$49.10B$303.97B
Dividend Yield
1.59%3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NRG Energy Inc

NRG Energy trades at $119.64, up 0.52% with a bullish technical signal despite recent earnings misses. The stock shows strong profitability metrics including 26.77% ROE and 2.56% net margin, supported by $30.71B revenue in 2025. Recent developments include a transformative 1.2 GW Texas data-center power project and LS Power acquisition, driving long-term growth expectations. Cash flow trends show volatility with 2025 net cash flow of $3.83B followed by projected 2026 outflow of -$264M.

Wall Street maintains strong bullish sentiment with 69% buy ratings and $201.29 consensus target, representing 68% upside. Key risks include rising interest costs impacting earnings, elevated debt levels at 56.42% debt-to-asset ratio, and execution challenges with major capital projects. The data center expansion strategy offers significant growth potential but requires careful monitoring of capex and leverage management.

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NRG Energy Inc

NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.

Read more on NRG

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS